These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 39252787)

  • 1. Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.
    Brúgós B; Simon Z; Méhes G; Illés Á; Pfliegler G
    Pathol Oncol Res; 2024; 30():1611785. PubMed ID: 39252787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Unicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease.
    Karki NR; Arfa AS; Savage N; Kutlar A
    Acta Haematol; 2022; 145(2):214-220. PubMed ID: 34818661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of unicentric Castleman disease with neoadjuvant rituximab.
    Bandera B; Ainsworth C; Shikle J; Rupard E; Roach M
    Chest; 2010 Nov; 138(5):1239-41. PubMed ID: 21051400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of Castleman disease.
    Soumerai JD; Sohani AR; Abramson JS
    Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
    Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
    Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Galicier L; Schleinitz N
    Rev Med Interne; 2022 Dec; 43(10S1):10S26-10S33. PubMed ID: 36657940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Castleman disease: retrospective single-center study of therapeutic results in 10 patients].
    Szturz P; Adam Z; Rehák Z; Koukalová R; Sprláková-Puková A; Michalka J; Smardová L; Volfová P; Lengerová M; Mayer J
    Klin Onkol; 2013; 26(2):124-34. PubMed ID: 23718671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.
    Basnayake BMDB; Wazil AWM; Kannangara T; Ratnatunga NVI; Hewamana S; Ameer AM
    J Med Case Rep; 2017 May; 11(1):135. PubMed ID: 28501028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
    Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
    Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
    Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
    Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Castleman Disease.
    Abramson JS
    J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1417-1419. PubMed ID: 31766018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
    Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
    Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy.
    Chronowski GM; Ha CS; Wilder RB; Cabanillas F; Manning J; Cox JD
    Cancer; 2001 Aug; 92(3):670-6. PubMed ID: 11505414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of Castleman Disease.
    Wu D; Lim MS; Jaffe ES
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):37-52. PubMed ID: 29157618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.